3 REITs That Drive America's $1.65 Trillion Life Science Dominance

Life Science REITs are currently facing headwinds due to higher interest rates impacting biotech funding and leasing demand, leading to negative sentiment in the sector; however, potential interest rate cuts could reignite VC funding and demand for space. Alexandria Real Estate (ARE), with its strong market position and high-quality tenant base, and Healthpeak (DOC), benefiting from its diversified healthcare portfolio, are expected to rebound with rate cuts, while Kilroy Realty Corporation (KRC) faces a more modest outlook due to a weaker growth profile. Artificial intelligence is also expected to drive demand for laboratory facilities with significant data storage requirements.

Analysis

The specialized life science real estate sector is currently navigating a challenging period characterized by slowed leasing demand, primarily due to higher interest rates impacting the capital-intensive biotech industry, which heavily relies on venture capital (VC). Since Q1-22, an increase in sublease space has exerted downward pressure on rents, with VC funding shifting towards larger, later-stage deals, tempering demand from smaller, early-stage biotechs. However, the fundamental demand for medical innovation remains robust, with over 90% of known diseases lacking approved treatments and advancements like AI expected to boost demand for specialized lab facilities with significant data storage. Alexandria Real Estate (ARE), an S&P 500 constituent and first-mover in life science REITs, reported Q1-25 revenue growth of 4% and adjusted EBITDA growth of 5%, with FFO per share at $2.30. Despite a strong tenant base (87% of top 20 tenants investment-grade or large-cap) and high rent collection (99.9% in Q1-25), ARE's occupancy dipped to 91.7% (down 2.9% QoQ) due to specific move-outs, leading to a 70 bps reduction in year-end 2025 occupancy guidance to 91.7% and a $0.07 reduction in FFO per share guidance to $9.26. ARE maintains a strong balance sheet with $5.3 billion in liquidity and is trading at a historically low 7.2x P/AFFO multiple with a 7.8% dividend yield. Healthpeak (DOC) is leveraging its diversified portfolio, where strong Q1-25 performance in Outpatient Medical (92% occupied) and Senior Housing (16% same-store growth) is offsetting current softness in its life science segment (35% of income). DOC generated FFO of $0.46 per share in Q1-25, maintained its 2025 FFO guidance of $1.81-$1.87, and is trading at 10.4x P/AFFO with a 7.2% dividend yield, supported by strategic asset sales ($1.4 billion at a 6.3% cap rate) and share buybacks ($300 million at an implied 8% cap rate). Kilroy Realty Corporation (KRC), with 17% of its portfolio in life science and 54% in technology, reported Q1-25 FFO per share of $1.02 and a 160 bps year-over-year decline in cash same-property NOI. KRC maintained its 2025 FFO guidance midpoint at $3.95 (-13.9% YoY) and faces a weaker growth outlook, with analysts forecasting a further 12% AFFO/share decline in 2026. A primary catalyst for sector recovery across all three REITs is anticipated to be interest rate cuts, which are expected to reignite VC funding flows and subsequently, leasing demand. JLL estimates 45 million square feet of vacant life science space nationally, requiring significant absorption for market equilibrium.

Key Decisions for Investors

• Investors should monitor interest rate trends and venture capital funding levels as key leading indicators for a potential rebound in the life science REIT sector, given the current valuation discounts.
• Alexandria Real Estate (ARE) presents a compelling long-term investment case due to its market leadership, high-quality portfolio, and strong balance sheet, despite recent occupancy and FFO guidance adjustments; its current 7.2x P/AFFO multiple may offer an attractive entry point for patient capital.
• Healthpeak (DOC) offers a more diversified approach, with its robust Outpatient Medical and Senior Housing segments providing stability while its life science portfolio is positioned for recovery; its proactive capital recycling and share repurchases are positive signals.
• Kilroy Realty Corporation (KRC) warrants a more cautious stance due to its significant office exposure and weaker near-term growth projections for its life science segment, though it could benefit from AI-driven tech leasing and an eventual broader life science upturn.
• Consider the long-term growth driven by medical innovation and AI's increasing role in R&D, which could stimulate demand for specialized laboratory facilities, potentially benefiting REITs with modern, adaptable assets.